Evidence map›Paper›PMID 36977707›Full record

ArticleCell death & disease2023

Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer.

V Nieddu, V Melocchi, C Battistini, G Franciosa, M Lupia, C Stellato, G Bertalot, J V Olsen, N Colombo, F Bianchi and 1 more

Open access · goldFull text read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

V NiedduUnit of Gynaecological Oncology Research, European Institute of Oncology IRCSS, Milan, Italy.ORCID 0000-0002-3300-074X
V MelocchiCancer Biomarkers Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.ORCID 0000-0001-9656-3681
C BattistiniUnit of Gynaecological Oncology Research, European Institute of Oncology IRCSS, Milan, Italy.ORCID 0000-0003-3583-290X
G FranciosaProteomics Program, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-5309-5558
M LupiaUnit of Gynaecological Oncology Research, European Institute of Oncology IRCSS, Milan, Italy.ORCID 0000-0002-4712-3708
C StellatoUnit of Gynaecological Oncology Research, European Institute of Oncology IRCSS, Milan, Italy.
G BertalotUnità Operativa Multizonale di Anatomia Patologica, APSS, Trento, Italy.ORCID 0000-0002-4862-7705
J V OlsenProteomics Program, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-4747-4938
N ColomboDivision of Gynecologic Oncology, European Institute of Oncology IRCSS, Milan, Italy.
F BianchiCancer Biomarkers Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.ORCID 0000-0001-7412-8638
U CavallaroUnit of Gynaecological Oncology Research, European Institute of Oncology IRCSS, Milan, Italy. ugo.cavallaro@ieo.it.ORCID 0000-0002-0884-6460
European Institute of Oncology · ITCasa Sollievo della Sofferenza · ITUniversity of Copenhagen · DKUniversity of Trento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) displays the highest mortality among gynecological tumors, mainly due to early peritoneal dissemination, the high frequency of tumor relapse following primary debulking, and the development of chemoresistance. All these events are thought to be initiated and sustained by a subpopulation of neoplastic cells, termed ovarian cancer stem cells (OCSC), that are endowed with self-renewing and tumor-initiating properties. This implies that interfering with OCSC function should offer novel therapeutic perspectives to defeat OC progression. To this aim, a better understanding of the molecular and functional makeup of OCSC in clinically relevant model systems is essential. We have profiled the transcriptome of OCSC vs. their bulk cell counterpart from a panel of patient-derived OC cell cultures. This revealed that Matrix Gla Protein (MGP), classically known as a calcification-preventing factor in cartilage and blood vessels, is markedly enriched in OCSC. Functional assays showed that MGP confers several stemness-associated traits to OC cells, including a transcriptional reprogramming. Patient-derived organotypic cultures pointed to the peritoneal microenvironment as a major inducer of MGP expression in OC cells. Furthermore, MGP was found to be necessary and sufficient for tumor initiation in OC mouse models, by shortening tumor latency and increasing dramatically the frequency of tumor-initiating cells. Mechanistically, MGP-driven OC stemness was mediated by the stimulation of Hedgehog signaling, in particular through the induction of the Hedgehog effector GLI1, thus highlighting a novel MGP/Hedgehog pathway axis in OCSC. Finally, MGP expression was found to correlate with poor prognosis in OC patients, and was increased in tumor tissue after chemotherapy, supporting the clinical relevance of our findings. Thus, MGP is a novel driver in OCSC pathophysiology, with a major role in stemness and in tumor initiation.

Indexed as

Hedgehog ProteinsOvarian NeoplasmsAnimalsCalcium-Binding ProteinsCell Transformation, NeoplasticExtracellular Matrix ProteinsFemaleHumansMatrix Gla ProteinMiceNeoplasm Recurrence, LocalTumor MicroenvironmentCalcium-Binding ProteinsExtracellular Matrix ProteinsHedgehog ProteinsMatrix Gla Protein

Identifiers

PMID36977707
PMCPMC10050398
OpenAlexW4361225218

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read84
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.